Furthermore, 1% and 50% cut-off values are specific to the 22C3 PD-L1 clone in non-small cell lung cancer (NSCLC) and in the current clinical are recommended as thresholds for patient stratification for immunotherapy. Here, CD274 is linked to non-small cell lung carcinoma.